API Chemical Development and Manufacturing

E.SOLVE accelerates your journey to the clinic supporting as early as possible your formulation strategy from discovery to market approval.
· When you deal with a challenging API, partner with Evotec’s screening experts to guide your process through every challenge along the drug discovery and devel...

Accelerated drug development through interdisciplinary integration and expert coordination of all drug development activities “under one roof”
Industry-leading timeline from candidate nomination to regulatory submission
Custom-designed, flexible development plans allow for real-time adjustments a...

• Industry leading approach to integrate critical path activities for the most efficient delivery of IND-enabled clinical candidates, in multiple disease areas and therapeutic modalities • Fully integrated, modality-agnostic resources from ideation through to development incorporating critical com...

J.POD SOLUTIONS providing partners with unmatched flexibility to quickly and cost-effectively produce high quality early phase clinical to commercial biologic drug substances

In this series of interviews, we speak to the teams behind the winning concepts at CPHI Pharma Awards 2022, in each of the different categories, from digital innovation to CEO of the year. 

Step behind the scenes and meet the brilliant minds driving innovation at Evotec as they revolutionize the search for quality hits in drug discovery. Witness the lightning speed at which groundbreaking solutions are found, transforming the landscape of pharmaceutical research. 

For more information, please visit: www.evotec.com/hit-identification.

Together, the companies will aim to put forward new research projects against infectious diseases and antimicrobial resistance, potentially creating new therapies and technologies.

Evotec has established a dedicated gene therapy-based R&D site in Orth an der Donau, Austria with the immediate focus of spearheading a partnership with Japan’s Takeda to support its research projects, the German drug discovery firm said Monday.